The Fidelity
Knowledge Hub.

We partnered with a mid-sized biotech to repurpose an approved dermatology drug for an ophthalmic indication, securing FDA alignment through a 505(b)(2) pathway and enabling accelerated development with reduced cost and risk.

We partnered with a biotechnology company developing a therapeutic asset for a rare neuromuscular disorder in a pediatric population to secure Orphan Drug Designation (ODD) from FDA and EMA -unlocking development incentives and market exclusivity.

We partnered with a biotechnology company to successfully publish the clinical study results of their oncology NCE in a high-impact, peer-reviewed journal-enhancing scientific credibility, supporting regulatory positioning, and Increasing visibility within the oncology community

FHS enabled a global pharmaceutical company to confidently integrate an acquired PV system through an independent, inspection-ready due diligence audit.

Transforming Global PV Operations: From Legacy Migration to Automated, Inspection-Ready, Multi-System Excellence.

FHS delivered comprehensive country-specific PV services in the CIS regions, navigating complex multi-jurisdictional regulatory requirements.

End-to-end case processing with escalating volume — delivered 100% on time with zero critical observations.

Delivering 107+ aggregate reports in stringent timelines during the COVID-19 pandemic without compromising quality.

FHS deployed a dedicated FTE team for US and EU market entry — system setup, SOPs, and first-case readiness in 8 weeks.